Citadel Advisors’s OncoSec Medical Incorporated ONCS Stock Holding History

Citadel Advisors’s Portfolio ONCS Stock Details ONCS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-623	Closed	-$29K	–	15557
2021 Q3	$29K	Buy	+623	New	+$31.6K	﹤0.01%	13584

Other funds holding ONCS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Salzhauer Michael $292M AUM 30% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's ONCS Position: Q4 2022 in Review

Citadel Advisors sold out of OncoSec Medical Incorporated (ONCS) in Q4 2022, closing a stake of 711 shares — an estimated $8K sold.

Citadel Advisors first reported a position in ONCS in Q1 2017 and held it in 16 quarters. The position peaked at $86K in Q1 2021. 17 funds tracked by Wall St. Rank hold ONCS as of Q4 2022.

Citadel Advisors reported no remaining OncoSec Medical Incorporated position as of Q4 2022 after selling out during the quarter.
Citadel Advisors sold 711 OncoSec Medical Incorporated shares in Q4 2022, an estimated $8K.
Citadel Advisors first reported a position in OncoSec Medical Incorporated in Q1 2017 and held it in 16 quarters.
Citadel Advisors's OncoSec Medical Incorporated position peaked at $86K in Q1 2021.
17 funds tracked by Wall St. Rank held OncoSec Medical Incorporated as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.